A drug developed by Indianapolis-based Eli Lilly and Co. (NYSE: LLY) has received its fourth approval from the U.S. Food and Drug Administration in as many years.
The FDA has approved a supplemental Biologics License Application for Taltz, for the treatment of pediatric patients with moderate to severe plaque psoriasis who are candidates for systemic therapy or phototherapy.
Dr. Jennifer Cather with Modern Research Associates in Texas says half of patients treated with Taltz saw completely clear skin after 12 weeks of treatment in a Phase 3 study.
“At Lilly, we are working to unite our compassion for individuals with our enthusiasm for scientific discovery in an effort to provide medicines that help make life better for people,” said Patrik Jonsson, senior vice president and president of Lilly Bio-Medicines. “We have over five years of data demonstrating that Taltz is a safe and effective treatment option for psoriasis in adults, and with this approval, we’re pleased to now be able to offer Taltz to more people living with this challenging condition.”
Taltz was first approved by the FDA in March 2016. The drug was also approved for the treatment of adults with active psoriatic arthritis in 2017, as well as adults with active ankylosing spondylitis two years later.